Varian Receives Investigational Device Exemption (IDE) for Flash Technology Clinical Trial, FAST-02

Flash therapy delivers radiation at ultra-high dose rates in typically less than one second and is capable of being over 100 times faster compared to conventional radiation therapy 

Related Keywords

University Of Cincinnati ,Ohio ,United States ,Cincinnati ,Deepak Dee Khuntia ,Siemens Healthineers ,Anthony Zietman ,Varian Probeam ,Johnc Breneman ,Jeffreyt Chapman ,Walter Curran Jr ,University Of Cincinnati Cancer Center ,Drug Administration ,Flash Solutions At Varian ,Cincinnati Children Uc Health Proton Therapy Center ,Flashforward Consortium ,Investigational Device Exemption ,Feasibility Study ,Symptomatic Bone Metastases ,Cincinnati Children ,Proton Therapy Center ,Medical Director ,Cincinnati Cancer Center ,Agam Sharda ,Vice President ,Flash Solutions ,Senior Vice President ,Chief Medical Officer ,Oncology Content ,Radiation Therapy ,Oncology Technologies ,Radiopharmaceutical Therapy ,Ana Kiess ,Technologies Aids Therapy ,Walter Curran ,